TG THERAPEUTICS, INC.— Sankey Diagram
Annual mode · period ending 2025-12-31 · SEC EDGAR
FY2025 - Q4(Oct 25 · Nov 25 · Dec 25)
Total Assets
$1.06B
↑+84.1% +$486Mvs FY2024
Total Liabilities
$415M
↑+16.9% +$60Mvs FY2024
Equity
$648M
↑+191.4% +$426Mvs FY2024
Cash
$79M
↓-56.0% -$101Mvs FY2024
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 | FY2024 |
|---|---|---|
| Total Assets | $1.06B | $578M |
| Current Assets | $631M | $566M |
| Cash | $79M | $180M |
| ST Investments | $63M | $131M |
| Receivables | $306M | $129M |
| Inventory | $126M | $110M |
| Other Current | $58M | $16M |
| Non-Current Assets | $432M | $11M |
| PPE | $0 | $0 |
| Goodwill | $0 | $0 |
| Intangibles | $0 | $0 |
| Investments | $59M | $808K |
| Other Non-Current | $373M | $11M |
| Total Liab+Eq | $1.06B | $578M |
| Current Liab. | $154M | $91M |
| Accounts Payable | $0 | $0 |
| Short-Term Debt | $0 | $0 |
| Deferred Revenue | $21M | $11M |
| Other CL | $133M | $79M |
| Non-Current Liab. | $261M | $265M |
| Long-Term Debt | $246M | $244M |
| Other LT Liab. | $16M | $20M |
| Equity | $648M | $222M |
| Retained Earnings | $1.08B | $1.53B |
| Other Equity | $0 | $0 |
QuarterCharts · SEC EDGAR data · TGTX · Comparing FY2025 vs FY2024